For efficient transfection of cell lines, e.g. A549, Caco-2, CHO-K1, HT-, or U-87 MG, in the Nucleofector® I/II/2b Device
For use in combination with TheraPEAK® Nucleocuvette® Cartridges, supporting the use of the 4D-Nucleofector® LV Unit in a GMP environment.
For use in combination with TheraPEAK® Nucleocuvette® Cartridges, supporting the use of the 4D-Nucleofector® LV Unit in a GMP environment.
For efficient transfection of cell lines, e.g. HepG2, HL-60, Jurkat, K-562 , MCF7, SH-SY5Y, or THP-1, in the NucleofectorTM I/II/2b System
Do you need a quote right away? Add this product to your shopping cart, go to your cart and click on “Generate Quote”. Your quote will be available straight away to view, save online, and download in PDF format.
For efficient transfection of specific primary cells, e.g. human T cells, CD34 or rat neurons, in the 4D-Nucleofector® X Unit (100 µL format).
-
Inducible Cas9 T Cells: An Innovative Platform for Allogeneic CAR-T Cell GenerationPoster on inducible Cas9 T Cells
-
Synthego_Lonza_Protocol_Genome Editing of Resting T cellsTechnical Protocol on Genome Editing of Resting T cells for associated White Paper "Genome Editing of Resting T cells"
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.
-
PBMC Based T Cell Proliferation AssayProtocol instructions
-
Instructions for Use – TheraPEAK® T-VIVO® Cell Culture Medium for Gamma Delta (γδ) T CellsInstructions for how to culture gamma delta (γδ) T Cells using TheraPEAK® T-VIVO® Cell Culture Medium
-
Instructions for Use - Dendritic Cell (DC) and T Cell Assay from Matched PBMCsProtocol for DC and T Cell Assay from Matched PBMCs
-
Case Study – Improving the Expansion of Patients' T CellsIn this serum-free media case study, learn how selection of memory T cells can aid in streamlining CAR-T therapies.
-
cGMP Kit T Optimization Protocol - Nucleofector™ 1/2 Device SeriescGMP Cell Line Nucleofector Kit T
-
Synthego-Lonza Genome Editing of Resting T cellsCase Study on Genome Editing of Resting T cells
-
A Novel Chemically Defined Medium Supports Superior Cross-platform T-cell ExpansionThis poster showcases how the chemically defined TheraPEAK® T-VIVO® Medium supports superior T-cell expansion across different platforms.